Why the study?
Does bacampicillin improve clinical outcomes in patients with acute simple cystitis, acute simple pyelonephritis, chronic prostatitis, and acute gonorrhoic urethritis?
Does bacampicillin improve clinical outcomes in patients with acute simple cystitis, acute simple pyelonephritis, chronic prostatitis, and acute gonorrhoic urethritis?
Bacampicillin showed excellent or good clinical effects in the majority of patients with urological infections, though gastrointestinal and allergic side effects occurred.
May support bacampicillin in select urological infections; hypothesis-generating and should not change practice without randomized trials.
A clinical investigation was carried out on a new penicillin derivative, bacampicillin with the following results. (1) Clinical effect--Bacampicillin was administered orally to 18 patients with acute simple cystitis, acute simple pyelonephritis, chronic prostatitis and acute gonorrhoic urethritis. Daily doses ranged from 750 mg to 1,000 mg. The administration continued for 4 to 14 days. Clinical effect was excellent in 10 patients and good in 5 patients. (2) Side effect--Side effects were noticed in 4 patients, one was allergic eruption and other 3 were gastralgia. In a patient the drug was discontinued to administer.
No takes yet. Share an insight, caveat, or question.
Someya et al. (1979) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: